Last reviewed · How we verify
NCT06091384
Inspiratory Muscle Strength Training in Post-Covid Syndrome
NA trial testing Inspiratory muscle strength training in Cardiovascular Abnormalities in 40 participants. Status unknown.
30 September 2024
Quick facts
| Lead sponsor | D'Or Institute for Research and Education |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 16 October 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Inspiratory muscle strength training
Conditions studied
- Cardiovascular Abnormalities — all drugs for Cardiovascular Abnormalities →
- Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →
- Physical Exercise — all drugs for Physical Exercise →
Sponsor
D'Or Institute for Research and Education
Who can join
Adults 18 to 65, any sex, with Cardiovascular Abnormalities or Post-COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with post-Covid-19 syndrome are at high risk of developing cardiovascular diseases 12 months after acute infection of COVID-19. We recently revealed that these patients have elevated muscular sympathetic nerve activity (MSNA), vascular dysfunction, impaired cardiac diastolic function, and reduced functional capacity. Considering that these outcomes are independent predictors of cardiovascular mortality, it is urgent to restore the cardiovascular health of these patients. High resistance inspiratory muscle strength training (IMST) at 75% of pressure inspiratory (PImax) performed at home (5 min/session, 5-7 times/week per 6 weeks) reduces the MSNA, improves the endothelial function and lowers blood pressure in different populations. Based on these findings, IMST (75% PImax) is an excellent therapeutic option for patients with post-COVID-19 syndrome. Therefore, the aim of the present proposal is to test whether IMST (75% PImax) reduces sympathetic activity, improves vascular function, and restores cardiac function, evoking an increase in functional capacity in patients with post-COVID-19 syndrome. To test these hypotheses we will conduct a randomized, double-blind, sham-controlled clinical trial to test these hypotheses.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06091384
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Inspiratory muscle strength training
Trials testing the same drug.
- NCT05938127 — Impact of Respiratory Training in Lymphoma Survivors · NA · terminated
- NCT05744817 — Reduced Volume of Inspiratory Resistance Training · NA · withdrawn
- NCT04848675 — Novel Time-efficient Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure · NA · unknown
- NCT04832165 — Inspiratory Muscle Training on Diaphragm Thickness, Inspiratory Muscle Pressure and Physical Function · NA · completed
- NCT03501355 — Effects of Inspiratory Muscle and Endurance Training in Heart Failure Patients With Pacemaker · NA · completed
Other recruiting trials for Cardiovascular Abnormalities
Currently open trials in the same condition.
- NCT07061509 — Exercise Addiction and Health Risks in Gym Users · recruiting
- NCT07400224 — Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease · Phase 1, PHASE2 · recruiting
Other D'Or Institute for Research and Education trials
Trials by the same sponsor.
- NCT07372144 — Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment · Phase 3 · not yet recruiting
- NCT07074106 — TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC · Phase 2 · recruiting
- NCT06725537 — Comprehensive Demographics and Clinical Profile of NSCLC Patients · not yet recruiting
- NCT06002841 — Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure · Phase 1, PHASE2 · unknown
- NCT05975957 — Photobiomodulation Therapy to Reduce Pain and Inflammation in Patients With Gonarthrosis · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06091384 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by D'Or Institute for Research and Education
- Last refreshed: 19 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06091384.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing